Kymera Therapeutics Inc’s filing revealed that its Chief Executive Officer Mainolfi Nello unloaded Company’s shares for reported $1.83 million on Oct 29 ’25. In the deal valued at $60.99 per share,30,000 shares were sold. As a result of this transaction, Mainolfi Nello now holds 660,482 shares worth roughly $39.44 million.
Then, Mainolfi Nello bought 30,000 shares, generating $1,850,400 in total proceeds.
Before that, Gollob Jared sold 59,576 shares. Kymera Therapeutics Inc shares valued at $3,659,254 were divested by the Chief Medical Officer at a price of $61.42 per share. As a result of the transaction, Gollob Jared now holds 109,992 shares, worth roughly $6.57 million.
A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who remained covering the stock and in late October has reiterated a ‘”a Buy”‘ rating for it. Mizuho began covering KYMR with “an Outperform” recommendation on October 21, 2025. H.C. Wainwright maintained its rating on September 18, 2025. It rated KYMR as “a Buy”.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -3.43% to $59.72. Over the last five days, the stock has lost -1.86%. Kymera Therapeutics Inc shares have risen nearly 25.28% since the year began. Nevertheless, the stocks have risen 48.45% over the past one year. While a 52-week high of $63.96 was reached on 10/16/25, a 52-week low of $19.44 was recorded on 04/09/25.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 57.05, which if violated will result in even more drops to 54.39. On the upside, there is a resistance level at 62.87. A further resistance level may holdings at 66.03.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-10-15, growing by 0.66 million shares to a total of 8.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 7.46 million shares. There was a rise of 8.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 17, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
